FDA
-
-
-
-
-
-
-
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
-
-
-
-
-
-
-
Regeneron Pharma (REGN) PT Raised to $975 at Guggenheim
-
-
-
-
-
-
-
Regeneron and Tessera partner on gene editing therapy for rare disease
-
-
-
-
-
-
-
After-hours movers: NVIDIA, CoreWeave, Palo Alto Networks, and more
-
-
-
-
-
-
-
Regeneron reports positive phase 2 results for factor XI antibodies
-
-
-
-
-
-
-
Regeneron Pharma (REGN) PT Raised to $740 at Cantor Fitzgerald
-
-
-
-
-
-
-
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

